[1] 诸骏仁,高润霖,赵水平,等.中国成人血脂异常防治指南(2016 年修订版)[J].中国循环杂志,2016, 31(10):7-28.
[2] 崔娟,毛凡,王志会.中国老年居民多种慢性病共存状况分析[J].中国公共卫生, 2016, 32(1):66-69.
[3] Amaia C L, Beatriz P P, Francisca G R, et al.Multimorbidity, polypharmacy, referrals, and adverse drug events:are we doing things well?[J]. British Journal of Genera l Practice , 2012, 62(605): e821-e826.
[4] 路海棠. 他汀类药物致肌病的临床特点[J].临床荟萃,2015,30(12):1378-1382.
[5] 徐海燕,刘冬,王文刚,等.他汀类药物与常见心血管药物相互作用的研究进展[J].中国药房,2016,27(11):1582-1584.
[6] 刘晶晶,刘水平.他汀类药物相关肌病的特点及防治策略[J].中国药房,2014,25(14):1298-1300.
[7] Miura M, Otani K, Ohkubo T.Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam[J]. Xenobiotica, 2005, 35(5):455-465.
[8] 吴华. CYP3A4酶相关的临床药物相互作用[J].中国药物警戒,2016,13(5):286-290.
[9] Cohen J D, Brinton E A, Ito M K, et al.Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users[J]. J Clin Lipidol 2012, 6(3): 208.
[10] Ito M K, Maki K C, Brinton E A.Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study[J]. J Clin Lipidol 2014, 8(1): 69.
[11] Kashani A, Phillips C O, Foody J M, et al.Risks associated with statin therapy: a systematic overview of randomized clinical trials[J]. Circulation,2006,114(25): 2788.
[12] Mancini G B, Tashakkor A Y, Baker S.Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update[J]. Can J Cardiol,2013,29(12): 1553. |